[ALLIANZ] QoQ TTM Result on 30-Jun-2012 [#2]

Stock
[ALLIANZ] ALLIANZ MALAYSIA BHD
Announcement Date
17-Aug-2012
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2012
Quarter
30-Jun-2012 [#2]
Profit Trend
QoQ- 9.31%
YoY- 16.43%
Quarter Report
Latest QR
Upcoming QR
ALLIANZ's Result
ALLIANZ's Financial Summary
View:
Show?
TTM Result
31/03/13 31/12/12 30/09/12 30/06/12 31/03/12 31/12/11 30/09/11 CAGR
Revenue 3,270,182 3,147,599 3,034,359 2,935,075 2,837,768 2,751,664 2,678,944 14.20%
PBT 299,829 297,779 283,599 281,959 259,109 248,791 259,860 9.99%
Tax -91,548 -90,174 -86,783 -93,411 -86,626 -85,155 -87,738 2.87%
NP 208,281 207,605 196,816 188,548 172,483 163,636 172,122 13.54%
-
NP to SH 208,281 207,605 196,816 188,548 172,483 163,636 172,122 13.54%
-
Tax Rate 30.53% 30.28% 30.60% 33.13% 33.43% 34.23% 33.76% -
Total Cost 3,061,901 2,939,994 2,837,543 2,746,527 2,665,285 2,588,028 2,506,822 14.25%
-
Net Worth 1,893,292 1,818,723 1,786,383 1,744,806 1,688,332 1,372,592 1,231,240 33.18%
Dividend
31/03/13 31/12/12 30/09/12 30/06/12 31/03/12 31/12/11 30/09/11 CAGR
Div 10,191 10,191 8,096 8,096 8,096 8,096 5,384 52.95%
Div Payout % 4.89% 4.91% 4.11% 4.29% 4.69% 4.95% 3.13% -
Equity
31/03/13 31/12/12 30/09/12 30/06/12 31/03/12 31/12/11 30/09/11 CAGR
Net Worth 1,893,292 1,818,723 1,786,383 1,744,806 1,688,332 1,372,592 1,231,240 33.18%
NOSH 158,700 156,786 156,837 156,484 156,471 154,223 153,905 2.06%
Ratio Analysis
31/03/13 31/12/12 30/09/12 30/06/12 31/03/12 31/12/11 30/09/11 CAGR
NP Margin 6.37% 6.60% 6.49% 6.42% 6.08% 5.95% 6.42% -
ROE 11.00% 11.41% 11.02% 10.81% 10.22% 11.92% 13.98% -
Per Share
31/03/13 31/12/12 30/09/12 30/06/12 31/03/12 31/12/11 30/09/11 CAGR
RPS 2,060.60 2,007.57 1,934.71 1,875.63 1,813.60 1,784.20 1,740.65 11.89%
EPS 131.24 132.41 125.49 120.49 110.23 106.10 111.84 11.24%
DPS 6.50 6.50 5.25 5.25 5.25 5.25 3.50 51.03%
NAPS 11.93 11.60 11.39 11.15 10.79 8.90 8.00 30.49%
Adjusted Per Share Value based on latest NOSH - 156,484
31/03/13 31/12/12 30/09/12 30/06/12 31/03/12 31/12/11 30/09/11 CAGR
RPS 1,836.32 1,767.48 1,703.89 1,648.14 1,593.50 1,545.15 1,504.32 14.20%
EPS 116.96 116.58 110.52 105.88 96.85 91.89 96.65 13.54%
DPS 5.72 5.72 4.55 4.55 4.55 4.55 3.02 53.02%
NAPS 10.6315 10.2127 10.0311 9.7977 9.4806 7.7076 6.9138 33.18%
Price Multiplier on Financial Quarter End Date
31/03/13 31/12/12 30/09/12 30/06/12 31/03/12 31/12/11 30/09/11 CAGR
Date 29/03/13 31/12/12 28/09/12 29/06/12 30/03/12 30/12/11 30/09/11 -
Price 8.39 7.05 6.20 5.04 4.70 4.75 4.51 -
P/RPS 0.41 0.35 0.32 0.27 0.26 0.27 0.26 35.44%
P/EPS 6.39 5.32 4.94 4.18 4.26 4.48 4.03 35.93%
EY 15.64 18.78 20.24 23.91 23.45 22.34 24.80 -26.43%
DY 0.77 0.92 0.85 1.04 1.12 1.11 0.78 -0.85%
P/NAPS 0.70 0.61 0.54 0.45 0.44 0.53 0.56 16.02%
Price Multiplier on Announcement Date
31/03/13 31/12/12 30/09/12 30/06/12 31/03/12 31/12/11 30/09/11 CAGR
Date 17/05/13 22/02/13 23/11/12 17/08/12 24/05/12 24/02/12 18/11/11 -
Price 9.50 7.60 7.69 6.37 4.54 4.98 4.55 -
P/RPS 0.46 0.38 0.40 0.34 0.25 0.28 0.26 46.23%
P/EPS 7.24 5.74 6.13 5.29 4.12 4.69 4.07 46.76%
EY 13.81 17.42 16.32 18.92 24.28 21.31 24.58 -31.88%
DY 0.68 0.86 0.68 0.82 1.16 1.05 0.77 -7.94%
P/NAPS 0.80 0.66 0.68 0.57 0.42 0.56 0.57 25.32%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment